NVIDIA's 13F filing revealed it sold its entire stake in the company as part of a portfolio rebalancing.

JPMorgan upgraded the stock to Overweight, citing blockbuster potential for its drug REC-4881 and strong efficacy for REC-617, suggesting a potential 3x return.

Identified as a potential short squeeze candidate due to a 30% short interest and positive AI-developed drug data, despite dilution concerns. A 'max bearish' call from Jim Cramer is noted as a potential contrarian indicator.

Announced positive Phase 1b/2 results for its AI-developed drug REC-4881. Considered a potentially attractive opportunity due to positive news, investor interest from NVIDIA, and high (40%) short interest.

Set to release critical clinical data from its TUPELO Phase 1b/2 trial on December 8, 2025. The decision to host a webinar suggests potential confidence in positive data, which could trigger a significant price movement and a potential short squeeze.

NVIDIA's investment in the company highlights a strategic interest in the application of AI for drug discovery and the broader healthcare sector.

Mentioned as one of the heavily shorted, smaller-cap stocks that saw significant gains due to a 'risk-on' appetite and speculative fervor in the market.

Speaker is shorting the stock and believes it is 'basically worthless'.